Compare Sirius XM Holdings Inc (SIRI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs BIO-TECHNE Corp — how do they compare? Sirius XM Holdings Inc trades at $28.6 (market cap $9.70B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Sirius XM Holdings Inc pays the higher dividend (3.75%). Which is the better fit depends on your goals.
| SIRI | TECH | |
|---|---|---|
Market Cap | $9.70B | $11.24B |
Sector | Media | Health |
52-Week High | $32.59 | $72.29 |
52-Week Low | $19.92 | $43.31 |
Enterprise Value | $18.98B | $11.32B |
Dividend Yield | 3.75% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $29.91, showing minimal daily movement (+0.1%) with a bullish technical signal from moving averages. The company demonstrates stable fundamentals with a P/E of 12.01 and net income margin of 10.23%, though Q2 2026 earnings missed expectations. Recent news highlights dividend declarations and institutional activity, while cash flow trends show improvement with projected positive net cash flow for 2026.
The outlook remains cautiously optimistic with analyst consensus favoring Buy ratings (58%) and a $33.17 price target suggesting 11% upside. Key risks include competitive pressures in audio streaming and execution challenges, but strong cash flow generation and reduced leverage support shareholder returns through dividends and potential buybacks.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
